Table 1: Evidence for protective effects of Nrf2-activation in animal models of neurodegenerative disorders.

DiseaseAnimal modelMethod of Nrf2-activationReference

ALSG93A-SOD1 miceSynthetic triterpenoids (CDDO-ethylamide (CDDO-EA), CCDO-trifluoroethylamide (CDDO-TFEA))Neymotin et al., 2011 [29]
Alzheimer’s disease (AD)Intracerebroventricular infusion of Abeta peptides in ratsCurcuminFrautschy et al., 2001 [30]
ADTransgenic APP/PS1 miceTert-butylhydroquinone/adenoviral Nrf2 gene transferKanninen et al., 2008 [31]
ADTransgenic 19959 miceCDDO-methylamide (CDDO-MA)Dumont et al., 2009 [32]
ADTransgenic APP/PS1 miceIntrahippocampal injection of Nrf2-expressing lentiviral vectorKanninen et al., 2009 [33]
Parkinson’s disease (PD)MPTP-toxicity (mice)
Tert-butylhydroquinoneAbdel-Wahab, 2005 [34]
PDMPTP-toxicity (mice)
3-NP-toxicity (rats)
CDDO-MAYang et al., 2009 [35]
PDMPTP-toxicity (mice)Astrocytic Nrf2-overexpressionChen et al., 2009 [36]
PDAlpha-synuclein expressing Drosophila Nrf2-overexpression, Keap1-downregulationBarone et al., 2011 [37]
Huntington’s disease (HD)Transgenic N171-82Q miceCDDO-EA, CDDO-TFEAStack et al., 2010 [38]
HDCAG 140 knock in miceCurcuminHickey et al., 2012 [39]